I agree with everything you say, but “name and shame” is an effective tactic. Unfortunately, it will hurt FIG more than the others. There will benefits from the RC for customers, but also unintended consequences.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%